The World Health Organisation (WHO) recently released a Global Progress Report detailing the advancements made in increasing access to Hepatitis C diagnostics and treatment in low- and middle-income countries. The report highlights the importance of overcoming barriers to ensure that all individuals, regardless of their economic status, have access to life-saving treatments for Hepatitis C.
Studies conducted by experts in the field of Hepatitis C have shown that eradicating the Hepatitis C virus infection can reduce the risk of developing hepatocellular carcinoma, a form of liver cancer. Patients with advanced liver disease who achieve sustained virologic response after treatment for Hepatitis C have shown similar survival rates to the general population. However, there is a persistent increased risk of hepatocellular carcinoma for up to 10 years post-eradication in patients with cirrhosis or high FIB-4 scores.
Additionally, research has shown that the risk of developing hepatocellular carcinoma in Hepatitis C patients treated with direct-acting antiviral agents is significantly reduced. Furthermore, long-term risks of liver cancer in patients with advanced cirrhosis after Hepatitis C cure have been investigated, with promising results.
These findings underscore the importance of timely diagnosis and treatment of Hepatitis C to prevent the development of advanced liver disease and liver cancer. Efforts to increase access to diagnostics and treatment for Hepatitis C in low- and middle-income countries are crucial in reducing the global burden of liver disease and improving overall public health outcomes.
Note: The image is for illustrative purposes only and is not the original image associated with the presented article. Due to copyright reasons, we are unable to use the original images. However, you can still enjoy the accurate and up-to-date content and information provided.
